Proteon logo     Print Page | Close Window

SEC Filings

10-Q
PROTEON THERAPEUTICS INC filed this Form 10-Q on 08/07/2017
Entire Document
 
 

Proteon Therapeutics, Inc.

Condensed Consolidated Statements of Cash Flows

(in thousands)

(Unaudited)

 

   Six Months Ended June 30,
   2017  2016
Operating activities          
Net loss  $(12,106)  $(14,457)
Reconciliation of net loss to net cash used in operating activities:          
Depreciation   77    52 
Amortization of premium/discount on available-for-sale securities   1    71 
Unrealized gain on forward foreign currency contracts included in net income   -    (125)
Foreign currency remeasurement gain   279    21 
Stock-based compensation   1,712    1,812 
Changes in:          
Prepaid expenses and other assets   263    460 
Interest receivable   (12)   (26)
Accounts payable, accrued expenses and other current liabilities   (942)   730 
Net cash used in operating activities   (10,728)   (11,462)
Investing activities          
Purchases of available-for-sale investments   (13,360)   (26,718)
Proceeds from maturities of available-for-sale investments   4,920    32,414 
Purchase of property and equipment   (14)   (202)
Net cash (used in) provided by investing activities   (8,454)   5,494 
Financing activities          
Exercise of stock options   109    139 
Proceeds from issuance of common stock under ESPP   58    5 
Proceeds from issuance of common stock, net of issuance costs   1,287    - 
Net cash provided by financing activities   1,454    144 
Effect of exchange rate changes on cash   (279)   (21)
Decrease in cash and cash equivalents   (18,007)   (5,845)
Cash and cash equivalents, beginning of period   36,392    40,031 
Cash and cash equivalents, end of period  $18,385   $34,186 

 

 

The accompanying notes are an integral part of these unaudited condensed consolidated financial statements. 

 

 8